Written by Alexa Heathorn, MS, CNS, Science Writer. Twelve weeks of alpha-lipoic acid supplementation significantly reduced migraine severity, attack frequency, and headache impact while improving markers of mitochondrial metabolism and vascular inflammation in women with episodic migraines.

Migraines are a common neurological disorder affecting approximately 14.7% of the global population and 12% of individuals in the United States.¹ They are characterized by recurrent, throbbing headaches often accompanied by nausea, vomiting, and sensitivity to light.¹ Migraines are classified based on frequency, with episodic migraines occurring fewer than 15 days per month and chronic migraines occurring 15 or more days per month. Additionally, migraines may occur with aura, which includes reversible visual, sensory, or language disturbances, or without aura, in which these neurological symptoms are absent.¹

Although the exact cause of migraines remains unclear, several mechanisms have been proposed. Current evidence suggests that impaired mitochondrial energy metabolism, reduced oxygen delivery to tissues (hypoxia), hypersensitivity to nitric oxide, and abnormal cortical activity may contribute to migraine development.¹ Previous studies have reported abnormalities in mitochondrial function and vascular signaling in individuals with migraines, including elevated lactate levels and changes in nitric oxide and vascular cell adhesion molecule-1 (VCAM-1), markers associated with hypoxia and endothelial dysfunction.¹

Several nutrients known to support mitochondrial function, including magnesium, coenzyme Q10, riboflavin, and L-carnitine, have shown benefits in migraine prevention.¹ Alpha-lipoic acid (ALA), a mitochondrial cofactor with antioxidant and anti-inflammatory properties, has also demonstrated potential therapeutic effects in previous migraine studies.¹ However, no prior research has evaluated the effects of ALA supplementation on lactate levels, nitric oxide, VCAM-1, and clinical migraine symptoms in women with episodic migraines. To address this gap, researchers conducted a randomized, double-blind, placebo-controlled trial with a three-month follow-up to examine the effects of ALA supplementation on mitochondrial and vascular markers as well as migraine symptoms.¹

The study included 92 women between the ages of 20 and 50 years who were diagnosed with episodic migraine and had experienced symptoms for at least six months.¹ Participants were randomly assigned to receive either 300 mg of alpha-lipoic acid (ALA) twice daily for three months or an identical placebo.

Primary outcomes included headache severity, headache frequency, and duration of migraine attacks. Secondary outcomes included biochemical markers associated with mitochondrial and vascular function, including lactate, nitric oxide (NO), and vascular cell adhesion molecule-1 (VCAM-1). These measures were assessed at baseline and again at the end of the three-month intervention period.

The results were as follows:

• Migraine Severity: Headache severity decreased significantly in the ALA group compared with placebo (P < 0.001). Average severity scores declined from 8.20 to 4.72 in the intervention group.
• Migraine Frequency: The number of migraine attacks per month was significantly reduced in the ALA group compared with the control group (P = 0.001), decreasing from an average of 5.7 attacks per month to 3.3 attacks per month.
• Migraine Impact and Disability: Measures of headache-related quality of life improved significantly. Scores on the Headache Impact Test (HIT-6) and Migraine Headache Index Score (MHIS) decreased substantially in the ALA group compared with placebo (both P < 0.001), indicating reduced daily life disruption from migraines.
• Lactate Levels (Mitochondrial Function): Serum lactate levels decreased significantly in the ALA group compared with placebo (−6.45 mg/dL vs −2.27 mg/dL; P = 0.039), suggesting improved mitochondrial metabolism.
• VCAM-1 (Endothelial Inflammation): Levels of vascular cell adhesion molecule-1, a marker of vascular inflammation and endothelial dysfunction, decreased significantly in the ALA group compared with the control group (P = 0.025).
• Nitric Oxide: No statistically significant differences were observed between groups in nitric oxide levels after the intervention (P = 0.104).
• Attack Duration: While attack duration decreased within both groups, the difference between the ALA and placebo groups was not statistically significant (P = 0.303

The study population was limited to women between the ages of 20 and 50 with episodic migraine without aura, meaning the findings may not apply to individuals with chronic migraine, migraine with aura, or other headache disorders. The results may also not be generalizable to women experiencing significant hormonal transitions such as perimenopause, menopause, pregnancy, or the postpartum period, all of which can influence migraine patterns and underlying physiology. Additionally, the intervention lasted only three months, so it remains unclear whether the improvements in migraine symptoms and biochemical markers would persist with longer-term supplementation. The trial was conducted at a single clinical center, which may limit how broadly the findings apply to other geographic regions or healthcare settings. Finally, participants continued their prescribed migraine medications during the study, which may have influenced symptom improvements and makes it difficult to fully isolate the independent effects of alpha-lipoic acid supplementation.

This randomized, double-blind, placebo-controlled trial found that alpha-lipoic acid supplementation significantly reduced migraine severity, frequency, and overall headache impact in women with episodic migraines over a 12-week period. These improvements were accompanied by reductions in lactate and VCAM-1 levels, suggesting potential benefits for mitochondrial metabolism and vascular inflammation. While additional research is needed to confirm long-term effects and applicability to broader populations, these findings suggest that alpha-lipoic acid may be a promising adjunct strategy for supporting migraine management in women with episodic migraines.

Posted March 11, 2026.

Click here to read the full text study.

Alexa Heathorn, MS, CNS-c, is a clinical nutritionist specializing in metabolic health, hormonal balance, and gastrointestinal restoration through root-cause functional nutrition. She earned her master’s degree in Nutrition from Bastyr University and is currently a Certified Nutrition Specialist (CNS) candidate. Alexa also works as a research writer and functional health consultant, translating complex science into actionable strategies for practitioners and wellness companies. Learn more at www.bloomedwellness.com.

References:

1. Kelishadi MR, Naeini AA, Khorvash F, Askari G, Heidari Z. The beneficial effect of Alpha-lipoic acid supplementation as a potential adjunct treatment in episodic migraines. Sci Rep. 2022;12(1):271. Published 2022 Jan 7. doi:10.1038/s41598-021-04397-z